Perigon Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 17.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,701 shares of the biopharmaceutical company's stock after buying an additional 985 shares during the period. Perigon Wealth

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and three have

Global X Japan Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 5,650.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 920 shares of the biopharmaceutical company's stock after buying an additional 904 shares during the

ARS Investment Partners LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 28,769 shares of the biopharmaceutical company's stock after buying an additional 7,914 shares during the period.

Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)    Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation Paris and Tarrytown, NY, December 23, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose symptoms are inadequately controlled with existing therapy.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo

Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d'asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a considérablement réduit les exacerbations (de 54 % à 65 %) et amélioré la fonction pulmonaire (de 4,68 % à 5,32 %) par rapport au placebo Le Dupixent est le premier et le seul médicament biologique à démontrer une amélioration de la fonction pulmonaire dans ce groupe de jeunes patients dans une étude randomisée de phase 3 et il inhibe l'IL-4 et l'IL-13, deux facteurs clés et centraux de l'inflammation de type 2 Paris et Tarrytown, NY, le 23 décembre 2025.

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

Osaic Holdings Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 55.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,068 shares of the biopharmaceutical company's stock after purchasing an additional 6,073 shares during the

Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with Dupixent collaboration revenues set to increase as the accounting development balance is paid off by Q3 2026. Multiple pipeline catalysts are upcoming in 2026—including Fianlimab, Lynozyfic, and Trevogrumab + Semaglutide—that could accelerate growth and re-rate REGN's valuation.